Amgen

A Phase 3 Study of Inebilizumab in Participants With Primary Membranous Nephropathy

Phase 3Recruiting159 people1 Oct 2026clinicaltrials.gov

Comparing the Extent to Which Romosozumab (AMG 785) is Made Available in the Body When Administered as a Single SC Injection or as 2 SC Injections

Phase 1Recruiting308 people10 Sept 2026clinicaltrials.gov

NCT07803679

Phase 4Not yet recruiting308 people4 Sept 2026clinicaltrials.gov

Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)

Phase 3Recruiting3,200 people6 Jul 2026clinicaltrials.gov

Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)

Phase 3Recruiting950 people6 Jul 2026clinicaltrials.gov

NCT07366086

Phase 3Recruiting71 people26 Jan 2026clinicaltrials.gov

Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy

Phase 3Active, not recruiting250 people10 Nov 2025clinicaltrials.gov

Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

Phase 3Recruiting12,800 people25 Jun 2025clinicaltrials.gov

NCT06973109

CollaboratorPhase 2Withdrawn0 people15 May 2025clinicaltrials.gov

NCT06588153

Phase 4Active, not recruiting102 people19 Sept 2024clinicaltrials.gov

Single and Multiple Ascending Dose Study of AMG 513 in Participants With Obesity

Phase 1Completed82 people5 Sept 2024clinicaltrials.gov

NCT06533748

CollaboratorPhase 2Recruiting128 people1 Aug 2024clinicaltrials.gov

NCT06332014

Phase 4Active, not recruiting102 people26 Mar 2024clinicaltrials.gov

NCT06207682

Phase 1Completed32 people17 Jan 2024clinicaltrials.gov

NCT06140095

CollaboratorEarly phase 1Status unknown8 people18 Nov 2023clinicaltrials.gov

NCT06081153

CollaboratorEarly phase 1Not yet recruiting44 people13 Oct 2023clinicaltrials.gov

NCT06079476

Phase 4Completed100 people12 Oct 2023clinicaltrials.gov

NCT06004947

Phase 1Completed32 people22 Aug 2023clinicaltrials.gov

NCT05972551

Phase 3Active, not recruiting111 people2 Aug 2023clinicaltrials.gov

NCT05891119

Early phase 1Completed21 people6 Jun 2023clinicaltrials.gov